Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 13/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.64 |
| ▸ | KDR | P35968 | 9/20 | 0.64 |
| ▸ | FLT1 | P17948 | 6/20 | 0.64 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.59 |
| ▸ | CBFB | Q13951 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20625579 | 1.00 | FGFR1 (0.64) | FGFR1PDGFRBKDRFLT1FGFR3 | |
| SCHEMBL20625422 | 1.00 | FGFR1 (0.64) | FGFR1PDGFRBKDRFLT1FGFR3 | |
| SCHEMBL20624940 | 0.93 | FGFR1 (0.60) | FGFR1PDGFRBKDRFLT1FGFR3 | |
| SCHEMBL20624937 | 0.93 | FGFR1 (0.60) | FGFR1PDGFRBKDRFLT1FGFR3 | |
| SCHEMBL30424731 | 0.93 | FGFR1 (0.60) | FGFR1PDGFRBKDRFLT1FGFR3 | |
| SCHEMBL23326079 | 0.93 | FGFR1 (0.60) | FGFR1PDGFRBKDRFLT1FGFR3 | |
| SCHEMBL20625538 | 0.93 | FGFR1 (0.63) | FGFR1PDGFRBKDRFLT1FGFR3 | |
| SCHEMBL20625274 | 0.93 | FGFR1 (0.63) | FGFR1PDGFRBKDRFLT1FGFR3 | |
| SCHEMBL20625273 | 0.93 | FGFR1 (0.63) | FGFR1PDGFRBKDRFLT1FGFR3 | |
| SCHEMBL30424542 | 0.93 | FGFR1 (0.63) | FGFR1PDGFRBKDRFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384075-B2 | Quinolinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-12 | — | — | US | disclosed |
| US-11384075-B2 | Quinolinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-12 | — | — | US | disclosed |
| US-20210139470-A1 | New Quinolinone Compounds | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| US-20210139470-A1 | New Quinolinone Compounds | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| WO-2019001419-A1 | NEW QUINOLINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139470-A1 | New Quinolinone Compounds | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885PDGFRB 31/4885KDR 28/4885 |
| US-11384075-B2 | Quinolinone compounds | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885PDGFRB 23/4885KDR 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.